Abstract:One of the neuropathological hallmarks of Alzheimer's disease is the presence of β-amyloid (Aβ)-containing neuritic plaques. Aβ is produced by the proteolytic cleavage of the amyloid precursor protein by β- and γ-secretase enzymes. Thus, inhibition of β-secretase (BACE1) is a promising disease modifying approach for the treatment of Alzheimer's disease. Identification of orally-bioavailable, CNS-active small molecule BACE inhibitors is challenging. SCH 785532 is a novel, potent, non-peptidic, orally available and brain penetrant BACE inhibitor. Following acute administration in pre-plaque transgenic CRND8 (TgCRND8) mice over-expressing human amyloid precursor protein with two familial Alzheimer's disease mutations, SCH 785532 produced robust inhibition of plasma Aβ but only modestly reduced cortical Aβ levels. This study sought to determine if chronic treatment with this BACE inhibitor would reduce cortical Aβ levels as well as to assess the disease modifying potential of chronic BACE inhibition as measured by a reduction in plaque deposition and/or improvement in cognitive performance. Beginning at 6 weeks of age (pre-plaque), TgCRND8 mice were treated with vehicle or SCH 785532 (100 mg/kg/day, in diet) for 6, 12, 18 or 24 weeks (well into the plaque deposition period). This dose given in diet provided relatively constant exposure and robust inhibition of plasma Aβ. Following 12-24 weeks of treatment, SCH 785532 reduced total guanidine extracted cortical Aβ40 and Aβ42 levels by 30%. While total β-amyloid plaque burden was not dramatically changed with SCH 785532 treatment, mature Thioflavine S positive fibrillar Aβ containing plaques were reduced by 35% after 24 weeks of treatment. Increased microglia reactivity observed around Aβ plaques was not noticeably reduced by 24 weeks of treatment with SCH 785532. TgCRND8 mice treated with vehicle did not perform as well as non-transgenic vehicle-treated mice in the Morris water maze and 24 weeks of treatment with SCH 785532 moderately improved performance of the transgenic mice in this cognition model. Overall, the results of this study demonstrate that chronic BACE inhibition reduced brain Aβ levels, delayed the maturation of amyloid plaques, improved cognitive function and was well tolerated. This study provides support that inhibition of BACE may have disease-modifying potential in the clinic.

Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits Β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice

Copper accumulation and the effect of chelation treatment on cerebral amyloid angiopathy compared to parenchymal amyloid plaques

A New Chiral Pyrrolyl Alpha-Nitronyl Nitroxide Radical Attenuates Beta-Amyloid Deposition And Rescues Memory Deficits In A Mouse Model Of Alzheimer Disease

Treatment with 1, 10 Phenanthroline-5-Amine Reduced Amyloid Burden in a Mouse Model of Alzheimer's Disease

Copper Chelators Promote Nonamyloidogenic Processing of AβPP Via MT1/2/CREB‐dependent Signaling Pathways in AβPP/PS1 Transgenic Mice

Aqueous Dissolution of Alzheimer's Disease Aβ Amyloid Deposits by Biometal Depletion

A New Chiral Pyrrolyl α-Nitronyl Nitroxide Radical Attenuates β-Amyloid Deposition and Rescues Memory Deficits in a Mouse Model of Alzheimer Disease

C3N Nanodots Inhibits Aβ Peptides Aggregation Pathogenic Path in Alzheimer's Disease.

Rescue of Cognitive Deficits in APP/PS1 Mice by Accelerating the Aggregation of Β-Amyloid Peptide

The Double-Edged Role of Copper in the Fate of Amyloid Beta in the Presence of Anti-Oxidants.

Alzheimer's disease, beta-amyloid protein and zinc.

Characterization of Copper Interactions with Alzheimer Amyloid β Peptides

Effects of Cyclen and Cyclam on Zinc(ii)- and Copper(ii)-Induced Amyloid Beta-Peptide Aggregation and Neurotoxicity.

A cocktail of Cu 2+ - and Zn 2+ -peptoid-based chelators can stop ROS formation for Alzheimer's disease therapy

Evaluation of Copper Chelation Therapy in a Transgenic Rat Model of Cerebral Amyloid Angiopathy

Screening a Specific Zn(ii)-binding Peptide for Improving the Cognitive Decline of Alzheimer's Disease in APP/PS1 Transgenic Mice by Inhibiting Zn2+-mediated Amyloid Protein Aggregation and Neurotoxicity.

Liberation of copper from amyloid plaques: Making a risk factor useful for alzheimers disease treatment

P3‐299: Chronic Administration of a Novel BACE Inhibitor Reduced Brain Aβ Levels and Mature Plaques and Modestly Improved Cognition in Transgenic CRND8‐APPswe/ind Mice

Serum albumin-embedding copper nanoclusters inhibit Alzheimer's β-amyloid fibrillogenesis and neuroinflammation

The impact of chelating compounds on Cu2+, Fe2+/3+, and Zn2+ ions in Alzheimer's disease treatment

Characterization of Copper Interactions with Alzheimer Amyloid β Peptides: Identification of an Attomolar-Affinity Copper Binding Site on Amyloid β1-42